Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and ibrutinib in patients with relapsed or refractory Chronic Lymphocytic Leukemia. Its primary objective is to evaluate the anti-leukemic activity of the combination and the primary endpoint for efficacy is complete response rate. The secondary objectives are to assess the safety of the combination of IPH2201 and ibrutinib. The trial will be performed in the United States under the coordination of leading investigators at the Ohio State University.

36 to 45 patients are planned to be enrolled."

More: globenewswire.com/news-rele...

Other Checkpoint Inhibitor posts:

healthunlocked.com/cllsuppo...

healthunlocked.com/cllsuppo...

Neil

7 Replies

oldestnewest
  • Neil,

    Is this different than Abt-199? Different target?

    Jeff

  • Quite different Jeff and beyond my current understanding. As I understand it, the IPH2201 isn't actually targeting the CLL cells but a checkpoint inhibitor in T and Natural Killer Lymphocytes. The reasoning behind the trial design is that CLL cells express greater quantities of a protein (HLA-E) on their cell membrane which stops our T and Natural Killer (NK) Lymphocytes from recognising them as cancerous cells and killing them. The IPH2201 binds to the NGK2A checkpoint inhibitor in T and NK cells, blocking that inhibition by the CLL cells. That enables the T and NK cells to work in concert with the Ibrutinib to wipe out the CLL cells.

    en.wikipedia.org/wiki/HLA-E

    Neil

  • ABT-199 is a BCL2 inhibitor.. it turns on B cell apoptosis...

  • Maybe combine all three? 😳

  • Maybe it's a cure in the future.

    Irina

  • 🙏🏻🙏🏻🙏🏻🙏🏻🙏🏻🙏🏻

    Jeff

  • Thank you for posting. It is exciting to see the new developments arise. For those of us with CLL it is hope that as the effectiveness of one treatment runs out there can be another to follow.

You may also like...